卵巢癌化學治療之改進

Modified Regimens for Ovarian Cancer Chemotherapy

李耀泰(Yiu-Tai Li) ； 陳福民(Fu-Min Chen) ； 何民康(Man-Hong Ho) ； 鄭文雄(Wen-Hsiung Chen) ； 郭宗正(Tsung-Cheng Kuo)

《中華民國婦癌醫學雜誌》 2008年1期 (2008/04) Pp. 1-6

https://doi.org/10.7010/JGO.200804.0001

摘要

目前治療晚期卵巢癌之標準方法，都是先行減積手術，再以carboplatin和paclitaxel做化學治療。然則此種方法即使經積極治療，復發的機會仍高。最近研究許多新的化學藥物，包括gemcitabine、adriamycin、topotecan、oxaliplatin、lipososomal doxorubicin和口服藥etoposide，都被證明對治療無效或稪發之卵巢癌有效，如將這些藥物增加作爲第一線用藥，可能會增加晚期卵巢患者之生存率。

關鍵字

卵巢癌 ； 化學治療

並列摘要

Currently, the standard of care for women with newly diagnosed advanced ovarian cancer is surgical cytoreduction followed by chemotherapy with a carboplatin/paclitaxel doublet. Despite this aggressive approach is made, recurrence rate is still high. A number of other agents, including gemcitabine, adriamycin, topotecan, oxaliplatin, lipososomal doxorubicin, and oral etoposide have shown activity in patients with relapsed duration or refractory ovarian cancer. Therefore, further improvement in the efficacy of the first-line regimen is essential if further improvement of survival is to be realized. The addition of other active agents, while retaining full doses of paclitaxel and carboplatin offers an opportunity to improve efficacy in the management of advanced ovarian cancer.

並列關鍵字

ovarian cancer ； chemotherapy